Navigation Links
Pharmacyclics Announces Results of Registered Direct Offering
Date:6/17/2011

arbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations and beliefs regarding our future results or performance. Because these statements apply to future events, they are subject to risks and uncertainties. When used in this announcement, the words "anticipate", "believe", "estimate", "expect", "expectation", "should", "would", "project", "plan", "predict", "intend" and similar expressions are intended to identify such forward-looking statements. Our actual results could differ materially from those projected in the forward-looking statements. Additionally, you should not consider past results to be an indication of our future performance. For a discussion of the risk factors and other factors that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our annual report on Form 10-K and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our mission and goal is to build a viable biopharmaceutical company that designs, develops and commercializes novel therapies intended to improve quality of life, increase duration of life and resolve serious unmet medial healthcare needs; and to identify promising product candidates based on scientific development expertise, develop our products in a rapid, cost-efficient manner and pursue commercialization and/or development partners when and where appropriate.

Presently
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Third Quarter 2011
2. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
3. Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
4. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
5. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
6. Pharmacyclics, Inc. Rights Offering Oversubscribed
7. Pharmacyclics Announces Subscription Price for Rights Offering
8. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
9. Pharmacyclics Files Registration Statement for Rights Offering
10. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
11. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... D.C., September 30, 2014 Applying a well-known ... researchers at Harvard University has demonstrated the ability ... -- work that holds promise for making future, ... detailing the sides of next-gen rocket ships and ... light passes through oil in water, it becomes ...
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 long-travel ... for measuring displacement in rubber and other soft ... distance, the DSES-1000 can measure elongations up to ... mm. In addition, it achieves +/- 0.2 percent ... +/- 100 µm below 50-mm stroke. , The ...
(Date:9/30/2014)... , Sept. 30, 2014  RegeneRx Biopharmaceuticals, Inc. ... that it has received a Canadian Patent for ... Peptides.  This patent includes claims using thymosin beta ... actin-sequestering peptides for these purposes.  The patent will ... Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 2014  KemPharm, Inc., a clinical-stage specialty pharmaceutical ... proprietary new molecular entity (NME) prodrugs, announced today ... (USPTO) issued U.S. Patent No. 8,816,083 to KemPharm ... Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates of ... The patent, which extends through 2032, ...
Breaking Biology Technology:Taking thin films to the extreme 2Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... April 23 MedQuist Inc. (Nasdaq: ... services, today announces that it has completed the purchase ... Inc., MedQuist,s majority owner, has acquired the stock of ... the combined companies will offer unprecedented opportunities for healthcare ...
... April 23 Moffitt Cancer Center announces steadily growing ... chemotherapy for Non Small Lung Cancer patients.  Each year, more than ... , , ... in cells to predict response to cisplatin-based chemotherapy.   The correlation ...
... April 22 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" ... a complaint regarding its proposed merger with Datong Investment Inc ... Circuit for Palm Beach County , State of ... Yanlin Han , a director and Chief Executive Officer ...
Cached Biology Technology:MedQuist Announces Completion of Spheris Transaction 2MedQuist Announces Completion of Spheris Transaction 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 2Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 3Moffitt Cancer Center Announces Growing Interest in Recently Launched Prognostic Test for Non-Small Cell Lung Cancer 4Complaint Filed Regarding Proposed Merger 2Complaint Filed Regarding Proposed Merger 3Complaint Filed Regarding Proposed Merger 4
(Date:9/30/2014)... Evidence of the environmental effects of moorland burning is ... the subject, with the aim of relieving tensions on ... , The EMBER (Effects of Moorland Burning on the ... burning on moorland, which is practised predominantly to support ... impacts on peat hydrology, peat chemistry and physical properties, ...
(Date:9/30/2014)... captured the popular attention of both children and aquarium ... sold as dehydrated eggs, these tiny brine shrimp readily ... tank of salt water. , Physicists, though, are ... shrimp vertically migrate in large groups in response to ... night and retreating deeper during the day. , Two ...
(Date:9/30/2014)... New England Journal of Medicine reports positive ... drug crizotinib against the subset of lung cancer marked ... study of 50 patients with advanced non-small cell lung ... rate was 72 percent, with 3 complete responses and ... it takes for the disease to resume its growth ...
Breaking Biology News(10 mins):Grouse moor burning causes widespread environmental changes 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2
... ARBOR, Mich.---A new study of expectant mothers suggests that ... are present in many industrial and consumer products including ... alarming rise in premature births. Researchers at ... that women who deliver prematurely have, on average, up ...
... for a lazy partner by working harder to bring up their ... of parenting, says research by bird biologists at the University of ... to be involved in raising young, but it is very common ... to find out why, for some animals, parents stick together. ...
... is being officially opened today (3 July) by Nobel ... the Lord-Lieutenant of Norfolk. The Genome Analysis Centre ... the science of understanding the genetic makeup of organisms ... knowledge can then be used for developments that include ...
Cached Biology News:Chemicals in common consumer products may play a role in pre-term births 2Battle of the sexes benefits offspring, says research 2New national genome center launched 2New national genome center launched 3
These 96-well 0.2 ml thin-wall PCR plate caps are caps that are used to seal 96-well, 0.2 ml thin-wall PCR plates. Supplied as 300 caps....
... sequence analysis software with the DeCypher Engine accelerator ... you can perform searches like these from your ... database in under 6 days Align ... Use HMM analysis to compare 100,000 sequences ...
Mouse monoclonal antibody to FMN2 - formin 2...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Biology Products: